MB, Levis & Associates’s AbbVie ABBV Stock Holding History

MB, Levis & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$138K	Hold	547	–	–	0.05%	73
2026 Q1	$119K	Hold	547	–	–	0.05%	71
2025 Q4	$125K	Hold	547	–	–	0.05%	72
2025 Q3	$127K	Hold	547	–	–	0.05%	71
2025 Q2	$102K	Hold	547	–	–	0.04%	88
2025 Q1	$115K	Hold	547	–	–	0.05%	80
2024 Q4	$97.2K	Hold	547	–	–	0.05%	86
2024 Q3	$108K	Hold	547	–	–	0.05%	79
2024 Q2	$93.8K	Hold	547	–	–	0.05%	84
2024 Q1	$99.6K	Buy	547 +4	+0.7%	+$689	0.05%	85
2023 Q4	$84.2K	Buy	543 +4	+0.7%	+$583	0.05%	88
2023 Q3	$80.3K	Buy	539 +4	+0.7%	+$587	0.05%	91
2023 Q2	$72K	Buy	535 +6	+1%	+$880	0.05%	94
2023 Q1	$84.4K	Buy	529 +5	+1%	+$764	0.06%	88
2022 Q4	$84.7K	Buy	+524	New	+$80.3K	0.07%	82

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

MB, Levis & Associates's ABBV Position: Q2 2026 in Review

MB, Levis & Associates held its AbbVie (ABBV) position steady in Q2 2026 at 547 shares worth $138K. The position accounts for 0.05% of the portfolio, ranked #73.

MB, Levis & Associates first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

MB, Levis & Associates held 547 shares of AbbVie worth $138K as of Q2 2026.
MB, Levis & Associates left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.05% of MB, Levis & Associates's portfolio in Q2 2026, its #73 holding.
MB, Levis & Associates first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on MB, Levis & Associates's 13F filing for Q2 2026, filed 22 Jul 2026.